Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25658920 | 0.96 | SMPD1 (0.55) | SMPD1TAS1R3TAS1R1NR1H4THRB | |
| SCHEMBL25658909 | 0.92 | SMPD1 (0.53) | SMPD1TAS1R3TAS1R1NR1H4THRB | |
| SCHEMBL25658910 | 0.88 | SMPD1 (0.53) | SMPD1TAS1R3TAS1R1NR1H4THRB | |
| SCHEMBL25658911 | 0.84 | CTSH (0.50) | SMPD1NR1H4 | |
| SCHEMBL19983071 | 0.84 | TDP1 (0.48) | MEN1KMT2A | |
| SCHEMBL25658921 | 0.83 | SMPD1 (0.53) | SMPD1TAS1R3TAS1R1NR1H4THRB | |
| SCHEMBL25660461 | 0.82 | MAOB (0.44) | SMPD1TAS1R3TAS1R1NR1H4ERAP2 | |
| SCHEMBL25658905 | 0.82 | TAS1R3 (0.57) | TAS1R3TAS1R1ERAP2LNPEPERAP1 | |
| SCHEMBL25658922 | 0.80 | CTSH (0.50) | SMPD1NR1H4 | |
| SCHEMBL19983005 | 0.80 | TDP1 (0.48) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | SMPD1 1443/4885TAS1R3 1274/4885TAS1R1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.